Nkarta, Inc. cotiza a 2.17 USD y tiene una capitalización bursátil de $155M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for th…
| Periodo | 2026-11 | 2026-08 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.54 | $-0.37 | $-0.29 |
| Estimado | $-0.37 | $-0.36 | $-0.29 | $-0.30 |
| Sorpresa | — | -50.0% | -27.6% | +3.3% |
| Métrica | NKTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -33.3% | -40.4% | +7.1% |
| ROA | -25.8% | -32.0% | +6.3% |
| Current Ratio | 12.69 | 2.84 | +9.85 |
| Debt / Equity | — | 0.28 | — |